Angiogenesis: General mechanisms and implications for rheumatoid arthritis

Joint Bone Spine

Volumn 67, Issue 5, 2000, Pages 366-383

  Weber, A J ^a   De Bandt, M ^a  

^a INSERM   (France)

Author keywords

Angiogenesis; Endothelium; Hypoxia; Integrins; Metalloproteinases; Rheumatoid arthritis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; BATIMASTAT; CALCIUM CHANNEL BLOCKING AGENT; CAMPTOTHECIN; CGS 27023A; CHORIONIC GONADOTROPIN; CM 101; ESTRADIOL 3 METHYL ETHER; FUMAGILLOL CHLOROACETYLCARBAMATE; HORMONE; INTERLEUKIN 12; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; PACLITAXEL; PENTOSAN POLYSULFATE; PI 88; PRINOMASTAT; RETINOID; ROQUINIMEX; SQUALAMINE; SURAMIN; TAMOXIFEN; TANOMASTAT; TECOGALAN; THALIDOMIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ASTHENIA; BONE DESTRUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; INFLAMMATION; MEDIATOR RELEASE; NEUROLOGIC DISEASE; NONHUMAN; PANNUS; PATHOGENESIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; JOINTS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033724429     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (127)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Applied vascular biology: Can angiogenesis inhibitors help control malignant growth?
3. The rationale and future potential of angiogenesis inhlbitors in neoplasia
4. Promising new developments in cancer chemotherapy
5. Missing link in angiogenesis
6. Angiogenesis, neovascular proliferation and vascular physiopathology as targets for cancer therapy
7. Angiogenesis: Implications for rheumatoid arthritis
8. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: Passive responders or transformed aggressors
9. Angiogenese synoviale
10. Cellules endotheliales et inflammation synoviale
11. Angiogenesis as a possible elusive triggering factor in rheumatoid arthritis
12. 'Very early' rheumatoid arthritis. Why and how should it be studied?
13. Angiogenesis mediated by soluble forms of E-selectine and vascular cell adhesion molecule-1
14. Hypoxic-reperfusion injury in the inflamed human joint
15. Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure
16. Angiogenesis and arthritis
17. Focally regulated endothelial proliferation and cell death in human synovium
18. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriasic and reactive arthritis: A comparative quantitative morphometric study
19. Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis
20. Angiogenesis: A critical process in pathogenesis of RA. A role for VEGF?
21. Vascular endothelial growth factor, a cytokine modulating endothelial function in rheumatoid arthritis
22. Interleukin-8 as a macrophage-derived mediator of angiogenesis
23. VEGF, a potent and selective angiogenic agent
24. VEGF and its receptors
25. Intracellular pool of vascular endothelial growth factor in human neutrophils
26. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
27. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis
28. Vascular endothelial growth factor (VEGF) is expressed in severe and destructive arthritis: Immunohistochemical analysis in human synovial tissues
29. Biological roles of fibroblast growth factor-2 (FGF2)
30. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease
31. In situ detection of basic fibroblast growth factor by highly specific antibodies
32. Expression of basic fibroblast growth factor in synovial tissues from patients with rheumatoid arthritis: Detection by immunohistological staining and in situ hybridisation
33. Nitric oxyde mediates interleukin-1induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: A possible mechanism of pathological neovascularization in arthritis
34. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development
35. Defective hematopoiesis and vasculogenesis in transforming growth factor-β1 knock-out mice
36. L'activation du TGF-β latent, un mecanisme requis pour l'integrite vasculaire
37. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction
38. Regulation of synovial cell growth: Coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovials cells
39. Enhanced expression of transforming growth factor-beta and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis
40. Transforming growth factor type beta: Rapid induction of fibrosis, and angiogenesis in vivo and stimulation of collagen formation in vitro
41. Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications
42. Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis
43. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis
44. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth
45. In vitro and in vivo activation of endothelial cells by colony-stimulating factors
46. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid arthritis
47. Interleukin-8. A corneal factor that induces neovascularization
48. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis
49. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis
50. Expression of VEGF in synovial fibroblasts is induced by hypoxia and interleukin-1β
51. Hypoxia augments cytokine (transforming growth factor beta [TGFβ] and IL-1)-induced VEGF secretion by human synovial fibroblasts
52. Angiogenin, a potent mediator of angiogenesis: Biological, biochemical and structural properties
53. Angiogenin enhances actin acceleration of plasminogen activation
54. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities
55. Expression of basic fibroblast growth factor and angiogenin in arthritis
56. Biological functions of haptoglobin. New pieces to an old puzzle
57. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis
58. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondine
59. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
60. Specific inhibition of endothelial cell proliferation by thrombospondin
61. Thrombospondin modulates focal adhesions in endothelial cells
62. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis
63. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
64. Angiostatine: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
65. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
66. Identification of neovascularization from cartilage
67. Troponin I is present in human cartilage and inhibits angiogenesis
68. Inhibition of angiogenesis in vivo by interleukin 12
69. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA)
70. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis
71. Dual role of IL-12 in early and late stages of murine collagen type II arthritis
72. Biphasic regulation of the development of murine type II collagen-induced arthritis by interleukin-12: Possible involvement of endogenous interleukin-10 and tumor necrosis factor alpha
73. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
74. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis
75. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood
76. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation
77. Induction of intercellular adhesion molecule-1 by monocyte adhesion to endothelial cells in human culture system
78. A role for sialyl Lewis-X/ A glycoconjugates in capillary morphogenesis
79. The role of alpha v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
80. Integrins and signal transduction pathways: The road taken
81. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
82. Definition of two angiogenic pathways by distinct alpha integrins
83. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins
84. Altered integrin expression in rheumatoid synovial lining B cells: In vitro cytokine regulation of alpha 1 beta 1, alpha 6 beta 1 and alpha v beta 5 integrins
85. 3 antagonist
86. A role for angiogenesis in rheumatoid arthritis
87. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis
88. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
89. NF-kappa B mediates alpha v β 3 integrin-induced endothelial cell survival
90. Suppresion of p53 and p21WAF1/CIP1 expression by vascular cell integrin alphav beta3 during angiogenesis
91. Disruption of angiogenesis by PEX, a non catalytic metalloproteinase fragment with integrin binding activity
92. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
93. Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases
94. Complex role of matrix metalloproteinases in angiogenesis
95. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1)
96. Quantitative angiogenesis assays: Progress and problems
97. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment
98. A model of angiogenesis in the mouse cornea
99. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
100. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species
101. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis
102. Angiogenesis inhibition suppresses collagen arthritis
103. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combinaison with cyclosporin: Reduction of vascular endothelial growth factor (VEGF)
104. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, Taxol
105. Synthetic analogues of fumagillin inhibit angiogenesis and suppress tumor growth
106. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
107. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
108. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combinaison with cisplatin
109. TNP 470 (AGM-1470): Mechanisms of action and early clinical development
110. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins
111. The effect of thalidomide and 2 analogs on collagen-induced arthritis
112. Thalidomide is an inhibitor of angiogenesis
113. Angiogenesis inhibitor suppresses arthritis and preserves from bone destruction in a new transgenic mouse model of RA
114. Organ-specific disease provoked by systemic autoimmunity
115. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells
116. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells
117. Antiangiogenesis by cyclosporine
118. Cyclosporin-A inhibits human endothelial cells proliferation through interleukin-6-dependent mechanisms
119. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization?
120. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularizatlon by low-dose methotrexate
121. Thiol-containing compounds inhibit the production of monocyte/macrophage-derived angiogenic activity
122. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine
123. Chloroquine's modulation of endothelial cell activity induced with basic fibroblast growth factor and human serum: Effect on mitogenesis, protease production and cell migration
124. Angiogenesis inhibition by minocycline
125. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a nonmetalloproteinase-dependent mechanism
126. COX-2 inhibitors. A new class of antiangiogenlc agents
127. The clinical manipulation of angiogenesis: Pathology, side-effects, surprises, and opportunities with novel human therapies